| Market Capitalization (Millions $) |
201 |
| Shares
Outstanding (Millions) |
74 |
| Employees |
108 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-117 |
| Cash Flow (TTM) (Millions $) |
-6 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Nkarta Inc is a biotechnology company founded in 2015, and headquartered in South San Francisco, California, in the United States of America. The company is focused on the development of genetically modified natural killer cells called NKT cells, that can be used for the treatment of cancer.
Nkarta's expertise lies in the development of CAR-NK cells, which are genetically engineered natural killer cells that are designed to recognize and attack cancer cells in the body. The company has developed a proprietary platform technology that enables the precise modification of NKT cells to improve their therapeutic potential. The technology involves the use of an antibody fragment, known as a single-chain variable fragment (scFv), which is linked to a signaling domain. This scFv recognizes a specific protein expressed on the surface of cancer cells, and upon binding, it activates the signaling domain to trigger a response from the NKT cells.
The approach is an alternative to CAR-T cell therapy, which uses genetically modified T cells to target cancer cells. The advantage of NKT cells is that they have a broader range of receptors than T cells, which means they can target a variety of cancer cells. Additionally, NKT cells are less likely to cause severe side effects, such as cytokine release syndrome, which is commonly observed with CAR-T cell therapy.
The company has a pipeline of CAR-NK cell therapies in development for the treatment of various cancers, including hematologic malignancies and solid tumors. In 2021, Nkarta received FDA clearance to initiate a clinical trial of its CAR-NK cell therapy targeting relapsed or refractory acute myeloid leukemia.
Nkarta has partnerships with several organizations, including CRISPR Therapeutics, which is providing gene editing technology, and the Leukemia & Lymphoma Society, which is funding the development of CAR-NK cell therapies.
In summary, Nkarta Inc is a biotechnology company that is revolutionizing cancer treatment by developing CAR-NK cell therapies. The company's genetically modified natural killer cells have the potential to target a wide range of cancers, with fewer side effects than traditional CAR-T cell therapy. With a robust pipeline and partnerships to support its growth, Nkarta is poised to make a significant impact in the fight against cancer.
Company Address: 1150 Veterans Boulevard South San Francisco 94080 CA
Company Phone Number: 407-1049 Stock Exchange / Ticker: NASDAQ NKTX
|
32.69% 